12
May
GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced that it has initiated dosing of Alzheimer’s patients in a Phase 1b clinical trial of its lead product candidate, GC021109, a compound developed as a potential disease-modifying treatment. GliaCure’s innovative approach to treating…more »
23
Mar
On March 17, 2015 Biogen reported interim results of its recent clinical trial using an antibody to treat Alzheimer’s disease. These results were extremely encouraging as they demonstrated both significant reductions in amyloid and improvements in cognition in patients with Alzheimer’s disease. This success is certain to stimulate new enthusiasm for investing in clinical trials…more »
17
Mar
Glia-based approach to Alzheimer’s disease provides a novel opportunity for treatment GliaCure, a biotechnology company developing innovative therapies based on glial targets, announced today that it has been awarded a $1 million grant by the Alzheimer’s Drug Discovery Foundation (ADDF) to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease.…more »
18
Dec
I was very excited to read about research recently published by a group from Stanford regarding the potential role for microglia in Alzheimer’s disease (http://med.stanford.edu/news/all-news/2014/12/blocking-receptor-in-brains-immune-cells-counters-alzheimers.html). While the work by Karin Andreasson and her team focuses on a receptor protein called EP2, the underlying conclusions of her research – that restoring the activity of microglia to…more »
18
Nov
GliaCure’s lead product candidate for Alzheimer’s disease, GC021109, has been awarded Fast Track status by the FDA. Biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The Fast Track…more »
25
Sep
GliaCure today distributed the following press release: GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced today that has initiated dosing of healthy volunteers in a first-in-human Phase 1a clinical trial of its lead product candidate, GC021109, a novel compound developed as…more »
18
Sep
On Monday, September 8th 2014 I had the pleasure of meeting several GliaCure investors at our annual shareholders’ meeting. In addition to dealing with the normal business of this meeting we were able to update the shareholders on our latest progress and on our timeline for plans for 2015. I am always thrilled by the excitement of…more »
21
Aug
GliaCure President Phil Haydon was co-author of a paper published in the Proceedings of the National Academy of Sciences (Tang-Schomer et al, 2014) and featured recently in the New York Times (August 11, 2014). This paper described the creation and potential uses of synthetic 3-D brain-like tissue. This tissue, composed of a modular design of…more »
16
Aug
B round financing with new and existing investors will advance GliaCure’s Alzheimer’s clinical program GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, today announced that it has successfully completed a $5.8 million B round financing, exceeding its original goal of $5 million. This financing round…more »
16
Aug
Mr. Zakrzewski is a Seasoned Life Sciences Leader GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, announced today that it has appointed Joseph S. Zakrzewski to the Company’s Board of Directors. Mr. Zakrewski brings more than 20 years of experience to his new role as…more »